#United States #Houston #Osimertinib #Iterion Therapeutics #Tegavivint

Innovating Cancer Treatment: Iterion Therapeutics Presents Promising Phase 1b Data for Tegavivint and Osimertinib

In a groundbreaking study released on September 22, 2026, Iterion Therapeutics shared encouraging results from their Phase 1b clinical trial evaluating the efficacy of tegavivint in combination with osimertinib for treating metastatic EGFR-mutated non-small cell lung cancer (NSCLC). Conducted at The Ohio State University Comprehensive Cancer Center, the trial demonstrated a remarkable 79% objective response rate (ORR) among participants, significantly outperforming historical data for osimertinib when administered alone.

Overview of the Trial

The investigation, led by Dr. Regan Memmott, assessed 15 evaluable patients who had not yet undergone any treatment with EGFR tyrosine kinase inhibitors (TKIs). Participants received a combination of osimertinib, taken orally at a daily dose of 80 mg, coupled with intravenous doses of tegavivint, ranging from 3 to 8 mg/kg. Notably, tegavivint targets the β-catenin signaling pathway, aiming to eradicate drug-tolerant tumor cells that often contribute to treatment resistance.

The encouraging clinical findings include:

• - Complete Responses (CRs): 16% of patients achieving complete tumor regression, showcasing a dramatic improvement over historical CR rates.
• - Median Progression-Free Survival (mPFS): 19.9 months, with only 6 events recorded during the trial.
• - Median Overall Survival (mOS): A significant 48.8 months noted among participants.

Following the first four months of combined treatment, participants transitioned to osimertinib alone until disease progression.

Addressing Cancer Therapy Limitations

Dr. Rahul Aras, President and CEO of Iterion Therapeutics, expressed optimism regarding these results, indicating that they may provide crucial insights into overcoming persistent clusters of tumor cells that traditional therapies often overlook. He emphasized the potential of tegavivint to deepen responses to EGFR-targeted therapies.

Historical applications of EGFR TKIs, like osimertinib, while transformative, do not completely eliminate cancer in the metastatic setting. Drug-tolerant persister (DTP) cells often remain, leading to treatment resilience. The results of this trial bolster the theory that inhibiting β-catenin signaling alongside standard EGFR therapy can improve patient outcomes.

Safety Profile and Tolerability

The combination of tegavivint and osimertinib was well tolerated among participants, with no observed dose-limiting toxicities, severe adverse events, or any pneumonitis. Common mild adverse effects aligned with those typically seen with osimertinib treatment, including gastrointestinal issues, skin rashes, anemia, and fatigue.

Pharmacokinetic evaluations showed that tegavivint's presence in the body was dose-proportional and did not interfere negatively with osimertinib.

Implications for Future Cancer Treatments

As the cancer landscape evolves, targeting DTP cells offers a promising strategy to enhance the effectiveness of existing therapies. The successful preliminary results from this Phase 1b study represent a significant step forward, potentially paving the way for a new standard of care involving tegavivint in conjunction with EGFR TKIs. With ongoing research and clinical validation, Iterion Therapeutics remains committed to developing cutting-edge solutions for cancers fueled by aberrant β-catenin signaling.

This data has been shared at the ASCO 2026 conference, igniting discussions about the future dynamics in cancer treatment avenues.

Conclusion

Iterion Therapeutics' pioneering work highlights the importance of innovative approaches to persistent cancer challenges. The integration of tegavivint with traditional treatments like osimertinib could mark a shift toward more effective management strategies for patients battling EGFR-mutated NSCLC. With further studies on the horizon, the scientific community watches closely for what could be a transformative era in oncology.